Down‐regulation of RCC1 sensitizes immunotherapy by up‐regulating PD‐L1 via p27kip1/CDK4 axis in non‐small cell lung cancer. Issue 8 (25th February 2021)

• Record Type: Journal Article
• Authors: Zeng, Xiaozhu; Zhong, Maoxi; Yang, Yumeng; Wang, Zhi; Zhu, Yuxi
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 8(2021)
• Page Start: 4136
• Page End: 4147
• Publication Date: 2021-02-25
• Subjects: ICI -- non‐small cell lung cancer -- p27KIP1/CDK4 -- PD‐L1 -- RCC1; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.16383
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: In recent years, although Immune Checkpoint Inhibitors (ICIs) significantly improves survival both in local advanced stage and advanced stage of non‐small cell lung cancer (NSCLC), the objective response rate of ICI monotherapy is still only about 20%. Thus, to identify the mechanisms of ICI resistance is critical to increase the efficacy of ICI treatments. By bioinformatics analysis, we found that the expression of regulator of chromosome condensation 1 (RCC1) in lung adenocarcinoma was significantly higher than that in normal lung tissue in TCGA and Oncomine databases. The survival analysis showed that high expression RCC1 was associated with the poor prognosis of NSCLC. And the expression of RCC1 was inversely related to the number of immune cell infiltration. In vitro, knockdown of RCC1 not only significantly inhibited the proliferation of lung adenocarcinoma cells but also increased the expression levels of p27 kip1 and PD‐L1, and decreased the expression level of CDK4 and p‐Rb. In vivo, knockdown of RCC1 significantly slowed down the growth rate of tumour, and further reduced the volume and weight of tumour model after treated by PD‐L1 monoclonal antibody. Therefore, RCC1 could up‐regulate the expression level of PD‐L1 by regulating p27 kip1 /CDK4 pathway and decrease the resistance to ICIs. And this study might provide a new way to increase the efficacy of PD‐L1 monoclonal antibody by inhibiting RCC1.